EMA Recommends Extension of Indications for Inotuzumab Ozogamicin By Ogkologos - April 29, 2026 164 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of paediatric patients with CD22-positive B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR ¿Ahora qué? 10 maneras de adaptarse a la vida cotidiana después... December 23, 2021 ESMO Congress 2022, 9-13 September August 22, 2022 Living With Stage 4 Lung Cancer: How Genomic Testing Is Helping... March 15, 2022 Patient Guide in Testicular Cancer Now Available Also in French December 1, 2025 Load more HOT NEWS ΟΓΚΟΙ ΕΓΚΕΦΑΛΟΥ Five Questions with…Debra. Bowel Cancer Data Reinforce Need to Reduce Unnecessary Antibiotic Use [ESMO... Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity...
